Early immune modulation by single-agent trastuzumab as a marker of trastuzumab benefit.

ABSTRACT:

Background

Optimising the selection of HER2-targeted regimens by identifying subsets of HER2-positive breast cancer (BC) patients who need more or less therapy remains challenging. We analysed BC samples before and after treatment with 1 cycle of trastuzumab according to the response to trastuzumab.

Methods

Gene expression profiles of pre- and post-treatment tumour samples from 17 HER2-positive BC patients were analysed on the Illumina platform. Tumour-associated immune pathways and blood counts were analysed with regard to the response to trastuzumab. HER2-positive murine models with differential responses to trastuzumab were used to reproduce and better characterise these data.

Results

Patients who responded to single-agent trastuzumab had basal tumour biopsies that

SUBMITTER: Triulzi T 

PROVIDER: S-EPMC6288086 | biostudies-literature | 2018 Dec

REPOSITORIES: biostudies-literature